Eli Lilly Signs an Exclusive License Agreement with SciNeuro to Develop and Commercialize Alpha-synuclein Targeted Therapies in China
Shots:
- Lilly to receive up front- milestones- as well as royalties on the products developed and commercialize by SciNeuro. Lilly retains all rights outside Greater China
- SciNeuro to get an exclusive license to develop and commercialize alpha-synuclein targeted therapies in Greater China includes mainland China- Hong Kong- Macau- And Taiwan
- Alpha-synuclein directed therapies help to treat patients with Parkinson’s disease and related neurological disorders addressing the unmet medical need
Ref: Business Wire | Image: Eli Lilly
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com